GenVec Inc. To Present At The 27th Annual ROTH Conference

GAITHERSBURG, Md., March 2, 2015 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) today announced that its President and CEO, Douglas J. Swirsky, will present a corporate overview at the 27th Annual ROTH Conference at 12 Noon PST/9 a.m. EST on Monday, March 9, 2015.

The live and archived webcast of Mr. Swirsky's presentation will be available at the following link:  http://wsw.com/webcast/roth29/gnvc.   This link will also be available on GenVec's website.  To access, visit www.genvec.com, click on "Investors and Media," select the "Presentations" option under the "News/Events" menu, and click through the ROTH conference icon or accompanying text.  The webcast replay will be accessible for 90 days. 

About GenVec

GenVec is an entrepreneurial clinical-stage biopharmaceutical company focused on leveraging its proprietary adenovector gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines. The company is a pioneer in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine. GenVec's lead product, CGF166, is licensed to Novartis and currently in a Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. In addition to our internal and partnered pipeline, the company also licenses its proprietary technology platform, including vectors and production cell lines, for the development and manufacture of therapeutics and vaccines to the biopharmaceutical industry. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

Contact:         
GenVec, Inc.                           
Rena Cohen                
(240) 632-5501                      
rcohen@genvec.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genvec-to-present-at-the-27th-annual-roth-conference-300043185.html

SOURCE GenVec, Inc.